Biopsychosocial Framework for Addiction: Implications for Psychedelic Therapies

From Simple Models to Multidimensional Frameworks

Over the past four decades, addiction research has transitioned from single-circuit dopamine models to more complex frameworks that consider a multitude of factors. This shift recognizes that addiction is not merely a neurochemical imbalance but a multifaceted condition influenced by developmental, social, and mental health factors. The recent review published on June 11, 2026, in OpenAlex underscores the importance of integrating these diverse elements into a cohesive biopsychosocial framework.

The Role of Psychedelic-Assisted Therapies

Psychedelic-assisted therapies have emerged as promising interventions that align well with this multidimensional approach. These therapies, which include substances like psilocybin and MDMA, are being studied for their potential to facilitate profound psychological and emotional experiences that may help individuals address the root causes of their addiction. By targeting neurobiological, cognitive, and affective domains, psychedelics may offer a holistic treatment option that traditional models have overlooked.

Implications for Research and Policy

The adoption of a biopsychosocial framework in addiction research could lead to more precise and effective interventions. This perspective encourages researchers to explore the interplay between biological predispositions, psychological states, and social environments. Policymakers and healthcare providers might consider integrating these insights into treatment guidelines and funding priorities, potentially expanding access to psychedelic therapies in clinical settings.

Risks and Unknowns

Despite the promising nature of psychedelic-assisted therapies, several risks and unknowns remain. The long-term effects of these substances are not fully understood, and their use is still subject to significant legal and regulatory barriers in many jurisdictions. Additionally, the integration of these therapies into existing healthcare systems poses logistical and ethical challenges that must be carefully navigated.

Looking Ahead

As research continues to explore the potential of psychedelic-assisted therapies within a biopsychosocial framework, it is crucial for stakeholders to remain informed and engaged. Future studies should aim to elucidate the mechanisms by which psychedelics exert their effects and identify the populations that may benefit most. This evolving field holds the promise of transforming addiction treatment, but it requires a collaborative effort across disciplines to realize its full potential.